Scientific Sessions 2024  /  Gene Therapy in the Cardiology Clinic: Ready for Prime Time?  /  Gene Silencing: Targeting TTR in Amyloidosis as a Paradigm for Knocking Down Mutant Alleles
Logo

American Heart Association

  117
  0

Final ID:

Gene Silencing: Targeting TTR in Amyloidosis as a Paradigm for Knocking Down Mutant Alleles

  • Alexander, Kevin  ( Stanford University , Palo Alto , California , United States )
  • Garcia-pavia, Pablo  ( Hospital Puerta de Hierro , Majadahonda , Spain )
    • Author Disclosures:
    Kevin Alexander: DO have relevant financial relationships ; Consultant:Arbor Biotechnologies:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Prothena:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Intellia:Past (completed) ; Consultant:Alnylam:Active (exists now) | Pablo Garcia-Pavia: DO have relevant financial relationships ; Consultant:Pfizer:Active (exists now) ; Consultant:Rocket Pharmaceuticals:Active (exists now) ; Consultant:Biomarin:Active (exists now) ; Consultant:Lexeo:Active (exists now) ; Consultant:Edgewise:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:BMS:Active (exists now) ; Consultant:Intellia:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:ATTRalus:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Bridgebio:Active (exists now) ; Consultant:Alnylam:Active (exists now) ; Consultant:Ionis:Active (exists now) ; Consultant:NovoNordisk:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Gene Therapy in the Cardiology Clinic: Ready for Prime Time?

Monday, 11/18/2024 , 01:30PM - 02:45PM

Main Event

More abstracts on this topic:
Gene Therapy in 2024: What Are the Options?

Helms Adam, Rosanno Joseph, Giacca Mauro

So How Do We Determine the Right Strategy for the Right Patient?

Watkins Hugh, Seidman Christine

More abstracts from these authors:
Discussant: SCAN-MP

Alexander Kevin

How does the co-occurence of atrial fibrillation and amyloidosis impact management?

Witteles Ronald, Garcia-pavia Pablo

You have to be authorized to contact abstract author. Please, Login
Not Available